Neutrophil Extracellular Trap Production in Patients with Colorectal Cancer In Vitro
Table 1
Population characteristics.
Patient demographics
Age, median (IQR)
69.0 (63.0–75.0)
Gender, n (%), M/F
26/19 (57.8/42.2)
BMI, median (IQR), kg/m2
26.8 (22.5–28.7)
Smoking status, n (%), 1/2/3
9/9/27 (20.0/20.0/40.0)
ASA, n (%), 1/2/3/4
4/25/14/2 (8.9/55.6/31.1/4.4)
Comorbidity, n (%), 0/1/2/≥3
10/21/10/4 (22.2/46.7/22.2/8.9)
Medications, n, 1/2/3/4
21/9/11/7
CR-POSSUM (predicted mortality [%]), median (IQR)
2.5 (1.3–3.9)
Presentation
Presentation, n (%), 1/2
39/6 (86.7/13.3)
Cancer location, n (%), 1/2
27/18 (60.0/40.0)
Tumour characteristics
Neoadjuvant therapy, n (%), y
11 (24.4)
T-Stage, n (%), 0/1/2/3/4
2/2/9/22/9 (4.5/4.5/20.5/50.0/20.5)
N-Stage, n (%), 0/1/2
32/8/4 (72.7/18.2/9.1)
M-Stage, n (%), 0/1
42/2 (95.5/4.5)
Dukes’ stage, n (%), A/B/C/D
9/22/11/2 (20.5/50.0/25.0/4.5)
Differentiation, n (%), 1/2
39/5 (88.6/11.4)
Extramural venous invasion, n (%), y
14 (32.6)
y: yes; 1/2/3: active/former/never; 1/2/3/4: antihypertensive/β-antagonist/antiplatelet/oral hypoglycaemic; 1/2: symptomatic/screened; 1/2: colon/rectosigmoid junction and rectum; 1/2: well and moderately differentiated/poorly differentiated.
We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.
